You are viewing the site in preview mode
Skip to main content
|
Variables
|
Total (n = 113%)
|
Non-complication group (n = 80%)
|
Complication group (n = 33%)
|
Crude OR (95% CI)
|
Adjusted OR (95% CI)
|
|---|
|
Sex
| | | | | |
|
Male
|
51 (45.1)
|
31 (60.8)
|
20 (39.2)
|
2.432 (1.060–5.580)
| |
|
Female
|
62 (54.9)
|
49 (79.0)
|
13 (21.0)
|
Ref
| |
|
Age group (years)
| | | | | |
|
≤ 65
|
110 (97.3)
|
79 (71.8)
|
31 (28.2)
|
Ref
| |
|
> 66
|
3 (2.7)
|
1 (33.3)
|
2 (66.7)
|
5.097 (0.446–58.250)
| |
|
BMI (kg/m2)
| | | | | |
|
< 18.5
|
24 (21.2)
|
10 (41.7)
|
14 (58.3)
|
4.859 (1.834–12.875)
|
6.333 (1.957–20.500)
|
|
18.5–24.9
|
76 (67.3)
|
59 (77.6)
|
17 (22.4)
|
Ref
|
Ref
|
|
≥ 25
|
13 (11.5)
|
11 (84.6)
|
2 (15.4)
|
0.631 (0.127–3.126)
|
0.726 (0.120–4.381)
|
|
Smoking history
| | | | | |
|
No
|
97 (85.8)
|
73 (75.3)
|
24 (24.7)
|
Ref
| |
|
Yes
|
16 (14.2)
|
7 (43.8)
|
9 (56.2)
|
3.911 (1.315–11.633)
|
5.592 (1.519–21.334)
|
|
Smoking index
| | | | | |
|
< 400
|
4 (25.0)
|
2 (50.0)
|
2 (50.0)
|
Ref
| |
|
≥ 400
|
12 (75.0)
|
5 (41.7)
|
7 (58.3)
|
1.4 (0.144–13.568)
| |
|
Alcohol abuse
| | | | | |
|
No
|
108 (95.6)
|
77 (71.3)
|
31 (28.7)
|
Ref
| |
|
Yes
|
5 (4.4)
|
3 (60.0)
|
2 (40.0)
|
1.656 (0.264–10.397)
| |
|
Comorbidities
| | | | | |
|
No
|
91 (80.5)
|
67 (83.8)
|
24 (70.0)
|
Ref
| |
|
Yes
|
22 (19.5)
|
13 (14.1)
|
9 (30.0)
|
1.933 (0.733–5.095)
| |
|
Course of disease
| | | | | |
|
< 12 months
|
17 (15.0)
|
13 (76.5)
|
4 (23.5)
|
Ref
| |
|
12–120 months
|
66 (58.4)
|
46 (70.0)
|
20 (30.0)
|
1.413 (0.410–4.871)
| |
|
> 120 months
|
30 (26.5)
|
21 (70.0)
|
9 (30.0)
|
1.393 (0.355–5.459)
| |
|
Coinfection
| | | | | |
|
No
|
80 (70.8)
|
64 (80.0)
|
16 (20.0)
|
Ref
|
Ref
|
|
Aspergillus or NTM
|
33 (29.2)
|
16 (46.7)
|
17 (53.3)
|
4.250 (1.771–10.198)
|
4.036 (1.385–11.766)
|
|
MDR
| | | | | |
|
No
|
100 (88.5)
|
71 (71.0)
|
29 (29.0)
|
Ref
| |
|
Yes
|
13 (11.5)
|
9 (69.2)
|
4 (30.8)
|
1.088 (0.310–3.815)
| |
|
Severity of TDL
| | | | | |
|
Lobe = 1
|
31 (27.4)
|
22
|
9
|
Ref
| |
|
Lobe > 1
|
82 (72.6)
|
58
|
24
|
1.011 (0.407–2.512)
| |
|
Lung function*
| | | | | |
|
FVC%pred
| |
65.6 ± 16.7
|
61.5 ± 19.2
|
0.986(0.957–1.015)
| |
|
FEV1%pred
| |
57.5 ± 18.3
|
55.9 ± 18.0
|
0.995(0.969–1.022)
| |
|
MVV%pred
| |
56.8 ± 19.8
|
55.6 ± 17.1
|
0.997(0.972–1.023)
| |
|
DLCO%pred
| |
59.5 ± 16.5
|
55.8 ± 8.7
|
1.018(0.995–1.042)
| |
- Data are presented as mean (SD) or n (%) or median (range)
- Comorbidities include hypertension, diabetes and coronary heart disease. FEV1% pre, forced expiratory volume in one second as a percentage of predicted value; FVC % pre, forced vital capacity as a percentage of predicted value; MVV % pre, maximal voluntary ventilation as a percentage of predicted value; DLCO, lung diffusion capacity of predicted. In view of small sample size of patients with comorbidities, they are combined into one group for statistical analysis; * 23% (26/113) of the patients with massive hemoptysis underwent emergency surgery without preoperative pulmonary function examination, and 87 cases had pulmonary function examination results
- TDL tuberculosis destroyed lung, BMI body mass index, OR odds ratio, CI confidence interval, NTM nontuberculous mycobacteria, MDR multidrug resistance
